Celgene walks away from Oncomed’s navicixizumab
admin 21st September 2018 Uncategorised 0Celgene has decided not to exercise its option to license OncoMed’s bispecific antibody navicixizumab.
More: Celgene walks away from Oncomed’s navicixizumab
Source: News